{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Stempeucel",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nBuerger's disease as diagnosed by Shionoya criteria\nMales or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 yrs\nEstablished CLI in the study limb, clinically and hemodynamically confirmed as per Rutherford- III-5\nPatients in Rutherford- III-6 if gangrene extending maximally up to the head of metatarsal but limited to toes (Patients with wet gangrene must undergo wound debridement / amputation before screening)\nPatients having infrapopliteal occlusive disease with rest pain and ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment as per the investigators judgment (No option patients)\nAnkle Brachial Pressure Index (ABPI) \u2264 0.6 or ankle pressure \u2264 50 mm Hg or TcPO2 \u2264 40 mmHg in the foot of the study limb\nPatients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent and video consent, abide by the study requirements, and agree to return for required follow-up visits\n\nExclusion Criteria:\n\nPatients with CLI indicated for major amputation during screening\nAtherosclerotic PAD\nUlcers with exposure of tendon and/bone in the shin region\nPrevious above transmetatarsal amputation in study limb\nAny Lumbar sympathectomy procedure performed less than 90 days prior to the screening\nPatients with gait disturbance for reasons other than CLI\nDiagnosis of diabetes mellitus (type 1 or type 2)\nPatients having left ventricular ejection fraction < 35%\nPatients suffering from clinically relevant peripheral neuropathy\nHistory of Stroke or myocardial infarction\nPatients who are contraindicated for MRA\nPatients with deep vein thrombosis in any limb\nPatients who have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy\nDocumented terminal illness or cancer or any concomitant disease process with a life expectancy of <1 year\nPatients already enrolled in another investigational drug trial or completed within 3 months or those who have participated in any stem cell clinical trial\nPatient with known hypersensitivity to the constituents of the IMP - dimethyl sulfoxide (DMSO) or human serum albumin (HSA)\nHistory of severe alcohol or drug abuse within 3 months of screening\nHb% < 10 gm% for males, Hb% < 9 gm% for females, serum creatinine \u2265 2mg%, serum Total Bilirubin \u22652mg%\nPregnant and lactating women\nPatients tested positive for HIV 1, HCV, HBV, CMV, RPR"
                        ],
                        "EnrollmentCount": [
                              "90"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT01484574"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This study will evaluate the safety and efficacy of intramuscular injection of stempeucel(R) (Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells) in Critical Limb Ischemia due to Buerger's Disease"
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nBuerger's disease as diagnosed by Shionoya criteria\nMales or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 yrs.\nEstablished CLI in the study limb, clinically and hemodynamically confirmed as per Rutherford- III-5;\nPatients in Rutherford- III-6 if gangrene extending maximally up to the head of metatarsal but limited to toes (patients with wet gangrene must undergo wound debridement / amputation before screening) .\nPatients having infrapopliteal occlusive disease with rest pain and ischemic ulcer/necrosis (patients should have at least one measureable ulcer), who are not eligible for or have failed traditional revascularization treatment as per the investigators judgment (No option patients) .\nABPI \u2264 0.6 or ankle pressure \u2264 50 mm Hg.\nPatients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent and video consent, abide by the study requirements, and agree to return for required follow-up visits.\n\nExclusion Criteria:\n\nPatients with CLI indicated for major amputation during screening\nAtherosclerotic PAD\nUlcers with exposure of tendon and/bone in the shin region.\nPrevious above trans metatarsal amputation in study limb\nAny Lumbar sympathectomy procedure performed less than 90 days prior to the screening\nPatients with gait disturbance for reasons other than CLI\nDiagnosis of diabetes mellitus (type 1 or type 2)\nPatients having left ventricular ejection fraction < 35%\nPatients suffering from clinically relevant peripheral neuropathy\nHistory of stroke or myocardial infarction\nPatients who are contraindicated for MRA\nPatients with DVT in any limb.\nPatients who have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy\nDocumented terminal illness or cancer or any concomitant disease process with a life expectancy of <1 year\nPatients already enrolled in another investigational drug trial or completed within 3 months or those who have received stem cells in the past\nPatient with known hypersensitivity to the constituents of the stempeucel\u00ae- dimethyl sulfoxide (DMSO) or human serum albumin (HSA)\nHistory of severe alcohol or drug abuse within 3 months of screening\nHb% < 10 gm% for males, Hb% < 9 gm% for females, serum creatinine \u2265 2mg%, serum Total Bilirubin \u22652mg%\nPregnant and lactating women\nPatients tested positive for HIV 1 & 2, HCV, HBV, CMV, RPR antibodies and for HBsAg antigen"
                        ],
                        "EnrollmentCount": [
                              "0"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03056742"
                        ]
                  }
            ]
      }
}